We are engaged in discussions with a number of biopharmaceutical companies regarding partnership opportunities focused on our product pipeline, the use of our Hybrid mRNA Technology for the delivery of potential partners’ mRNAs and the use of Hybrid mRNA Technology for in vivo gene editing.
- In vivo instead of ex vivo delivery
- High levels of expression/activity
- Cell- and tissue-specific expression
- Polymer-targeted endosome escape with good tolerability
- Retained activity on repeat dosing to treat and manage chronic conditions